Press Releases

Date	Title
2/28/19	Pulse Biosciences Submits 510(K) to U.S. FDA for CellFX™ System
2/15/19	Pulse Biosciences Grants Equity Incentive Awards to New Employees
2/7/19	Pulse Biosciences Quarterly Investor Conference Call
1/28/19	Pulse Biosciences to Report Fourth Quarter and Full Year 2018 Operational Highlights and Financial Results
1/17/19	Pulse Biosciences Announces Two Appointments Focused on CellFX™ Commercialization: Promotion of Edward Ebbers and Addition of Robert Tyson
1/15/19	Pulse Biosciences Grants Equity Incentive Awards to New Employees
1/7/19	Pulse Biosciences Announces Positive Clinical Results of Its Nano-Pulse Stimulation™ Technology Platform to Treat Patients with Sebaceous Hyperplasia Lesions on the Face
12/17/18	Pulse Biosciences Grants Equity Incentive Awards to New Employees
12/14/18	Pulse Biosciences, Inc. Announces Closing of Its $45 Million Rights Offering
12/7/18	Pulse Biosciences, Inc. Announces Oversubscription, Pricing and Preliminary Results for Its $45 Million Rights Offering

Keyword Search